<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948789</url>
  </required_header>
  <id_info>
    <org_study_id>MARGI-T</org_study_id>
    <nct_id>NCT03948789</nct_id>
  </id_info>
  <brief_title>Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy</brief_title>
  <official_title>Multicenter, Randomized Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids (MRgFUS TUF) Compared to Myomectomy in Symptomatic Medication and Not Sufficiently Treatable Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to answer the question, whether in patients with symptomatic and&#xD;
      medically not sufficiently treatable uterine fibroids (population) the&#xD;
      &quot;Magnetic-Resonance-Guided Focused Ultrasound Surgery&quot; short, MRgFUS-TUF (intervention)&#xD;
      offers less burdensome therapy and patient-relevant advantages (symptom relief) compared to&#xD;
      the operative myomectomy (comparison). The study will hence investigate the therapeutic&#xD;
      benefit of this method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WAI question 4</measure>
    <time_frame>Until at least three consecutive days questionnaire was answered as indicated, up to 12 months</time_frame>
    <description>Time to sustainably return to normal activities, based on the daily Work Activity Index (WAI) dimension, &quot;Estimated Impairment of Disease Performance&quot;. The return to normal activities is considered to be given if the question &quot;Hindrance of medical condition or injury at work?&quot; (min max: 1: 'in my opinion, I am completely unable to work', 6: 'No Disability') is answered for at least three consecutive days with &quot;No Disability&quot; (6) or &quot;I can do my job, but have complaints&quot; (5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Severity Score of the UFS-QoL</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>The symptom severity is determined to be the co- primary endpoint for assessing therapeutic efficacy, based on the SSS (Symptom Severity Score) of the UFS-QoL (Uterine fibroid symptom and quality of life questionnaire). The co-primary assessment is performed 12 months after the primary treatment and for the evaluation the proportion of patients with at least 25 points improvement in the SSS is determined (0-100 scale, 100 indicating very strong symptoms, 0 no or low symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay in days</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain according to visual analog scale</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>Visual analog scale ranges from 0-100, 0 indicating no pain, 100 severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of postinterventional/postsurgery treatment complications</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-interventions</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alleviation of symptoms (irregular period, unfulfilled wish for child, pain, quality of life according to UFS-QoL</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>QoL: Quality of Life score regarding symptoms, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life according to UFS-QoL</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>QoL: Quality of Life score regarding health, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexuality related parameters according to UFS-QoL</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>QoL: Quality of Life score regarding sexuality, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pregnancies and live births</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of late complications like venous thromboembolisms within Follow up time frame</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fibroid recurrences (de novo fibroids) within Follow up time frame</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time period until return to normal physical activities, measured by the rate of patients, who achieved an a priori clinically relevant reduction of SSS of UFS-QoL</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>at timepoints: months 1, 3 and 6 compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">127</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>A Myomectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Removement of uterine fibroids by myomectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B MRgFUS-TUF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy</intervention_name>
    <description>Magnetic Resonance Imaging-controlled high-focussed ultrasound</description>
    <arm_group_label>B MRgFUS-TUF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myomectomy (laparoscopic or open surgical)</intervention_name>
    <description>Myomectomy (laparoscopic or open surgical)</description>
    <arm_group_label>A Myomectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with symptomatic and medically untreatable uterine fibroids who score at least&#xD;
             40 points on the Symptom Severity Score (SSS) of the Uterine Fibroid Symptom and&#xD;
             Quality of Life Questionnaire (UFS- QoL )&#xD;
&#xD;
          -  Safe access for the MRgFUS possible (anatomical position of the fibroids): Pelvic&#xD;
             magnetic resonance imaging to document the number, location and size of fibroids and&#xD;
             to exclude malignancy and other pelvic pathologies; necessary to determine whether&#xD;
             MRgFUS can be performed technically (presence of a stable ultrasound window and&#xD;
             exclusion of scars in the access path)&#xD;
&#xD;
          -  ≤ 5 fibroids requiring treatment&#xD;
&#xD;
          -  Fibroids with a diameter ≤ 10 cm&#xD;
&#xD;
          -  Total myoma volume ≤ 400 ml&#xD;
&#xD;
          -  Patient is suitable for treatment with MRgFUS-TUF as well as for myomectomy&#xD;
&#xD;
          -  Desire for least invasive treatment&#xD;
&#xD;
          -  Indication for hysteroscopy and fractionated abrasion depending on the bleeding&#xD;
             pattern and endometrial thickness and structure have been critically tested in&#xD;
             advance.&#xD;
&#xD;
          -  inconspicuous cytological smear of the cervix uteri not older than 12 months&#xD;
&#xD;
          -  No previous uterine surgery / intervention&#xD;
&#xD;
          -  Female patients aged&gt; 18 years. Patients of reproductive age must adhere to&#xD;
             appropriate contraception until 6 months after the procedure. (Methods of&#xD;
             contraception that meet the criteria of highly effective contraception in the sense of&#xD;
             the Note for guidance on non- clinical safety studies for the conduct of human&#xD;
             clinical trials for meet pharmaceuticals [CPMP / ICH / 286/95 mod ]). Patients of&#xD;
             childbearing potential must have a negative pregnancy test within 7 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Karnofsky index ≥ 70&#xD;
&#xD;
          -  Given medical operability&#xD;
&#xD;
          -  Written consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pretreatment with ulipristal acetate ( Esmya ) ≤ 2 months&#xD;
&#xD;
          -  Suspected Malignancy (absolute)&#xD;
&#xD;
          -  Pregnancy (absolute)&#xD;
&#xD;
          -  acute inflammatory process (absolute)&#xD;
&#xD;
          -  Uterus myomatosis with more than 5 fibroids (relative, case-by-case decision)&#xD;
&#xD;
          -  Uterine fibroids with a diameter over 10 cm (absolute)&#xD;
&#xD;
          -  insufficient sound window can be reached for treatment (eg intestinal overlays, large&#xD;
             scars in the acoustic window, very dorsal position of the fibroid)&#xD;
&#xD;
          -  subserous stalked fibroids&#xD;
&#xD;
          -  Inaccessible location of fibroids&#xD;
&#xD;
          -  Scarring in the treatment area&#xD;
&#xD;
          -  Recurring abortions&#xD;
&#xD;
          -  general contraindications to MR contrast agents&#xD;
&#xD;
          -  MRI contraindications&#xD;
&#xD;
          -  Presence of pacemaker or metal implants&#xD;
&#xD;
          -  Karnofsky Index &lt;70&#xD;
&#xD;
          -  Severe hepatic dysfunction (Aspartat-Aminotransferase (AST) / Transaminasen&#xD;
             Alanin-Amino-transferase (ALT)&gt; 3.5x ULN (upper limit of normal), Alkalische&#xD;
             Phosphatase (AP)&gt; 6xULN)&#xD;
&#xD;
          -  Active CHD (congenital heart disease), (symptoms present), cardiomyopathy or heart&#xD;
             failure in NYHA (New York Heart Association) and EF (ejection fraction) stage III-IV&#xD;
             &lt;45%&#xD;
&#xD;
          -  Serious internistic side-diseases or an acute infection&#xD;
&#xD;
          -  Chronic inflammatory bowel disease&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Participation in another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten O Götze, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thorsten O Götze, PD Dr. med.</last_name>
    <phone>06976014187</phone>
    <email>goetze.thorsten@khnw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Düx, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FOKUS Radiologische Gemeinschaftspraxis</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hunold, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leipzig University</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahriye Aktas, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Nikolaos Bailis</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Zähringer, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Manfred Hofmann, PD Dr.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.aerzteblatt.de/nachrichten/98991/Erster-G-BA-Auftrag-zu...1%20von%202%2027.11.2018%2014:10</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

